logo-loader
Amryt Pharma PLC

Orphan drug status for new compound 'great news' says Amryt Pharma PLC's COO

Amryt Pharma PLC (LON:AMYT) has been granted orphan drug status in the US for  a compound called AP102 to treat patients with the excess growth condition acromegaly. Chief operating officer Rory Nealon tells Proactive: ''Our focus is to acquire, develop and commercialise products in the orphan drug space ... acromegaly is exactly that, it is classified as an orphan condition with an estimated prevalence of 60 patients per million of population''.
''Orphan status is the same in Europe and the USA - it's designed to encourage companies like ourselves to develop treatments for rare conditions. We get marketing exclusivity and also don't require the same number of patients for clinical trials'', Nealon added. Amryt has already been awarded orphan drug status for its lead drug EpiSalven, to treat the skin disorder Epidermolysis Bullosa, which is being prepared for a phase III trial early next year.

Quick facts: Amryt Pharma PLC

Price: £1.34

Market: AIM
Market Cap: £67.51 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Hybridan’s Pearson cautions biotech investors against knee-jerk reactions to...

Hybridan’s Niall Pearson tells biotech investors that drug trial failure is ‘the nature of the beast’ and speaking with Proactive Investors he highlighted examples where selling has gone too far. “When companies have them [trial failures] there’s a big hooha and everyone forgets what they...

on 07/28/2016

2 min read